此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Individualized Blood Pressure Management in Patients Undergoing Cardiac Surgery (PRECISE)

Individualized Blood Pressure Management in Patients Undergoing Cardiac Surgery. A Pilot, Randomized Controlled Study

This pilot randomized-controlled study will determine the feasibility of large study comparing individualized versus standard blood pressure (BP) management in patients undergoing cardiac surgery under cardiopulmonary bypass (CPB). Our hypothesis is that maintaining higher BP levels based on preoperative measurements will reduce the incidence of major complications (composite outcome).

研究概览

详细说明

Adequate hemodynamic control is a cornerstone in management in patients undergoing different types of surgery. Among all perioperative risk factors, the association between perioperative hypotension and adverse clinical outcomes in noncardiac and cardiac surgery patients is well defined.

Numerous factors are responsible for development of perioperative hypotension. They include but not limited to perioperative use of renin-angiotensin-aldosterone system and calcium channel blockers, hypovolemia, hemodilution, bleeding and inflammatory response syndrome.

To date, several evidence has been accumulated indicating that intraoperational hypertension can be hazardous.

It was shown that even short durations (1 to 5 min) of an intraoperative mean arterial pressure < 55 mmHg were associated with myocardial injuries and acute kidney injury (AKI).

Results of recent large retrospective cohort study conducted in adult patients who underwent cardiac surgery requiring CPB showed that postoperative stroke was strongly associated with sustained mean arterial pressure of less than 64 mmHg during cardiopulmonary bypass.

In patients undergoing CABG the overall incidence of combined cardiac and neurologic complications was significantly lower in the group where MAP during CPB was relatively high (80-110 mmHg) than in the low pressure group (MAP 50-60 mmHg) (p = 0.026). For each of the individual outcomes the trend favored the high pressure group.

Therefore, MAP may be an important intraoperative therapeutic hemodynamic target to reduce the incidence of complications in patients undergoing CPB.

研究类型

介入性

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Novosibirsk、俄罗斯联邦、630055
        • Meshalkin Research Institute of Pathology of Circulation

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • ≥18 years old
  • Signed informed consent
  • Elective cardiac surgery under CPB (CABG or valve surgery)

Exclusion Criteria:

  • Unstable Coronary Artery Disease: Recent (< 6 weeks) myocardial infarction, unstable angina, severe (> 70%) left main coronary artery stenosis
  • Uncontrolled hypertension preoperatively (SBP > 160 mm Hg)
  • Critical preoperative state (ventricular tachycardia or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anesthetic room, hemodynamic instability, preoperative inotropes or intraaortic balloon pumping, preoperative severe acute renal failure (anuria or oliguria <10ml/hr)
  • Planned surgery on aorta
  • Emergency surgery
  • Pregnancy
  • Current enrollment into another randomized controlled trial (in the last 30 days)
  • Previous enrollment and randomization into current study
  • Glomerular filtration rate ≤59 ml/min/1.73m2 (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Individualized BP group
Individualized intraoperative BP management

In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP).

Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status.

安慰剂比较:Standard treatment group
Standard intraoperative BP management
Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Compliance with the protocol
大体时间:Operative day 1
Successful compliance with protocol is defined as ≥ 90% of prescribed intervention being administered across all patients.
Operative day 1
Successful recruitment rate
大体时间:12 month
Successful recruitment rate will be defined as recruitment of 2 patients per week.
12 month

次要结果测量

结果测量
措施说明
大体时间
Postoperative creatinine concentration
大体时间:3 days after surgery
Plasma creatinine level will be measured daily during 3 postoperative days.
3 days after surgery
Postoperative cardiac troponin I level
大体时间:12 hours after surgery
Cardiac troponin I level wil be measured in the time frame from 6 to 12 hours postoperatively.
12 hours after surgery
Intraoperative blood pressure
大体时间:Operative day 1
Intraoperative blood pressure (mean, systolic and diastolic) will be registered every 5 minutes intraoperatively using invasive blood pressure monitoring system.
Operative day 1
Rate of postoperative complications
大体时间:30 days after surgery
Postoperative complications (myocardial infarction, atrial fibrillation, stroke, delirium, need for renal replacement therapy, infection, reexploration for bleeding) will be defined according to standard European Society of Anaesthesiology/European Society of Intensive Care Medicine definitions where possible.
30 days after surgery
Postoperative blood loss
大体时间:Postoperative day 1
Drainage volume (ml/kg) will be measured in the next morning after surgery.
Postoperative day 1
Daily Sequential Organ Failure Assessment (SOFA) score
大体时间:30 days after surgery
Organ failure will be assessed by using Sequential Organ Failure Assessment (SOFA) score which will be recorded daily until patient discharge from the ICU. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). The score ranges from 0 to 24 points (the higher the score, the higher the mortality).
30 days after surgery
Peak concentration of lactate during CPB and up to 24 hours after surgery
大体时间:Postoperative day 1
Lactate values (mmol/l) will be measured every 6 hours during the first 24 postoperative hours.
Postoperative day 1
Oxygen delivery during CPB
大体时间:Operative day 1
Oxygen delivery during CPB will be calculated according to the standard formula (pump flow x O2 arterial content).
Operative day 1
Cerebral oxygenation (near infrared spectroscopy)
大体时间:Operative day1
Number of cerebral desaturations will be recorded intraoperatively.
Operative day1
Ventilation > 24 hours
大体时间:30 days after surgery
Number of patients with duration of ventilation more than 24 h.
30 days after surgery
Duration of ICU stay and hospitalization
大体时间:30 days after surgery
Number of postoperative days spent in the ICU and in the hospital will be counted.
30 days after surgery
30-day all-cause mortality
大体时间:30 days after surgery
Number of patients who will die within 30-day after surgery from any cause
30 days after surgery
Need for blood transfusions
大体时间:30 days after surgery
Number of patients who will need transfusions of any blood products (RBC, fresh frozen plasma, platelets, cryoprecipitate).
30 days after surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Vladimir Lomivorotov, MD, PhD、Meshalkin Research Institute of Pathology of Circulation

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年1月21日

初级完成 (预期的)

2020年3月10日

研究完成 (预期的)

2020年4月10日

研究注册日期

首次提交

2018年10月3日

首先提交符合 QC 标准的

2018年12月21日

首次发布 (实际的)

2018年12月24日

研究记录更新

最后更新发布 (实际的)

2019年11月22日

上次提交的符合 QC 标准的更新

2019年11月20日

最后验证

2019年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅